Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
57.1M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
6.09M
-
Shares change
-
-1.12M
-
Total reported value, excl. options
-
$32.8M
-
Value change
-
-$7.42M
-
Put/Call ratio
-
0.11
-
Number of buys
-
12
-
Number of sells
-
-13
-
Price
-
$5.39
Significant Holders of Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) as of Q4 2021
40 filings reported holding ATXS - Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2021.
Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.09M shares
of 57.1M outstanding shares and own 10.68% of the company stock.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (1.28M shares), RA CAPITAL MANAGEMENT, L.P. (1.26M shares), Fairmount Funds Management LLC (912K shares), Cormorant Asset Management, LP (553K shares), VR Adviser, LLC (539K shares), VANGUARD GROUP INC (533K shares), Alyeska Investment Group, L.P. (275K shares), CITADEL ADVISORS LLC (222K shares), Ikarian Capital, LLC (87.6K shares), and GEODE CAPITAL MANAGEMENT, LLC (65K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.